Cardiometabolic Health — Revenue
Eli Lilly Cardiometabolic Health — Revenue increased by 8.7% to $15.76B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 71.2%, from $9.21B to $15.76B. Over 3 years (FY 2022 to FY 2025), Cardiometabolic Health — Revenue shows an upward trend with a 49.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration, strong demand for metabolic therapies, and effective commercial execution, while a decrease may signal increased competition, patent expirations, or supply constraints.
Detailed definition
This metric represents the total gross sales generated from pharmaceutical products specifically indicated for the treat...
Peer comparison
Comparable to metabolic or diabetes-focused business unit revenues at major pharmaceutical peers, often benchmarked against market share in the GLP-1 and insulin therapeutic classes.
lly_segment_cardiometabolic_health_revenueHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.62B | $3.62B | $3.62B | $3.62B | $4.19B | $5.01B | $4.72B | $5.75B | $5.49B | $7.51B | $7.41B | $9.11B | $9.21B | $11.34B | $13.18B | $14.49B | $15.76B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +15.9% | +19.6% | -5.8% | +21.7% | -4.4% | +36.8% | -1.4% | +22.9% | +1.1% | +23.2% | +16.2% | +10.0% | +8.7% |
| YoY Change | — | — | — | — | +15.9% | +38.6% | +30.5% | +58.9% | +31.1% | +50.0% | +56.9% | +58.5% | +67.6% | +50.9% | +77.9% | +59.1% | +71.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's cardiometabolic health — revenue?
- Eli Lilly (LLY) reported cardiometabolic health — revenue of $15.76B in Q1 2026.
- How has Eli Lilly's cardiometabolic health — revenue changed year-over-year?
- Eli Lilly's cardiometabolic health — revenue increased by 71.2% year-over-year, from $9.21B to $15.76B.
- What is the long-term trend for Eli Lilly's cardiometabolic health — revenue?
- Over 3 years (2022 to 2025), Eli Lilly's cardiometabolic health — revenue has grown at a 49.4% compound annual growth rate (CAGR), from $14.46B to $48.22B.
- What does cardiometabolic health — revenue mean?
- The total revenue generated from the company's diabetes and cardiometabolic drug portfolio.